Publications by authors named "K Foon"

Claim this Profile
V
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
Carla Casulo, Jesse G Dixon, Jennifer Le-Rademacher, Eva Hoster, Howard S Hochster, Kenneth Foon

Blood· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
A R Mato, B T Hill, N Lamanna, P M Barr, C S Ujjani, K Foon

Ann Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Anthony R Mato, Kenneth A Foon, Tatyana Feldman, Stephen J Schuster, Jakub Svoboda

Am J Hematol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, Ian W Flinn, Andres Forero-Torres, Kenneth A Foon

Leuk Lymphoma· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
Mark H Kirschbaum, Kenneth A Foon, Paul Frankel, Christopher Ruel, Bernadette Pulone

Leuk Lymphoma· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis